ReviewJournal of fungi (Basel, Switzerland)2018
Pre-Existing Liver Disease and Toxicity of Antifungals.
Review in Journal of fungi (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Diagnosis, treatment, and biosafety protection of imported highly pathogenic cutaneous fungal infection: a case-based study of cutaneous coccidioidomycosis.Frontiers in public health · 2026Article
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- Design of an epitope-based peptide vaccine against Cryptococcus neoformans.FEBS open bio · 2024Article
- Antifungal pipeline: Is there light at the end of the tunnel?World journal of clinical cases · 2024Article
- Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections.Hepatology international · 2024Review
- Safety and efficacy of non-reduced use of caspofungin in patients with Child-Pugh B or C cirrhosis: a real-world study.Infection · 2024Article
- Guideline Adherence and Outcomes of Patients with Candidemia in Brazil.Journal of fungi (Basel, Switzerland) · 2024Article
- Evaluation of the antidermatophytic activity of potassium salts of N-acylhydrazinecarbodithioates and their aminotriazole-thione derivatives.Scientific reports · 2024Article
- Fungal infections and the fungal microbiome in hepatobiliary disorders.Journal of hepatology · 2023Review
- Case Series of End-Stage Liver Disease Patients with Severe Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.Frontiers in genetics · 2023Review
- Efficacy and safety of caspofungin for patients with hepatic insufficiency.BMC infectious diseases · 2022Article
- Pulmonary Coccidioidomycosis: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2022Review
- [Expert consensus on diagnosis and treatment of end-stage liver disease complicated infection (2021 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Polymeric microneedle-mediated sustained release systems: Design strategies and promising applications for drug delivery.Asian journal of pharmaceutical sciences · 2022Review
- Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.BMC veterinary research · 2021Article
- Pericarditis Caused byCase reports in critical care · 2021Article
- Chitooligosaccharides and Thermostable Chitinase Against Vulvovaginal Candidiasis and Saprophyte Fungi: LC Mass Studies of Shrimp Shell Fermentation by Bacillus altitudinis.Current microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current evidence to guide decision-making is limited. This comprehensive review aims to evaluate the existing evidence related to antifungal treatment in individuals with liver dysfunction. This article also provides suggestions for dosage adjustment of antifungal drugs in patients with varying degrees of hepatic impairment, after accounting for established or emerging pharmacokinetic⁻pharmacodynamic relationships with regard to antifungal drug efficacy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.